Ipatasertib

6 trials 2 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

3 Completed trials

4 Sponsors

10 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 1 Phase II: 4 Phase I (Other): 1

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Ovarian epithelial cancer 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 3 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 1 Queen Mary University Of London 1 Solti Group 1

All trials

6 total

BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab… Pending

2024-516236-10-00 Phase II 2 countries Queen Mary University Of London
Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study … Recruiting

2024-514022-23-00 Phase II 1 country Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting

2023-504263-16-00 Phase III 4 countries F. Hoffmann-La Roche AG
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended

2023-508194-89-00 Phase II 5 countries F. Hoffmann-La Roche AG
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Phase II 8 countries F. Hoffmann-La Roche AG
Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a… Ended

2023-508826-92-00 Phase I (Other) 1 country Solti Group

Showing 1–6 of 6 trials

← All drugs A–Z